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Ruben A Mesa1* and Jorge Cortes2Abstract
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk
myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow
fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces
splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for
the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as
compared with either placebo or what was previously considered best available therapy in the two phase III
studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and
thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies
shows that these hematologic events can be managed effectively with dose modifications, temporary treatment
interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for
permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient
management through careful monitoring of blood counts and dose titration as needed in order to maximize
treatment benefit.
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Myelofibrosis (MF), a Philadelphia chromosome-negative
myeloproliferative neoplasm, is characterized by progres-
sive bone marrow fibrosis and ineffective hematopoiesis
[1,2]. Clinical presentation may include splenomegaly,
anemia, and multiple burdensome chronic symptoms such
as night sweats, pruritus, early satiety, abdominal pain, left
subcostal pain, bone pain, profound fatigue (irrespective
of presence or degree of concomitant anemia), and cach-
exia [3,4]. Many of these symptoms appear to be associ-
ated with a pro-inflammatory state typical for patients
with MF [5], which is manifest by excessive levels of cir-
culating cytokines such as interleukin-6 and tumor ne-
crosis factor-α [6,7]. The molecular pathobiology of MF
is characterized by dysregulation of Janus kinase (JAK)/
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article, unless otherwise stated.signaling networks [8,9], which have crucial roles in
cytokine- and growth factor-mediated regulation of
cellular responses, including normal hematopoiesis and
inflammation [10,11]. Specifically, overactivation of JAK2
plays a role in malignant myeloproliferation, whereas aber-
rant JAK1 signaling contributes to many of the additional
clinical and laboratory characteristics of the disease, includ-
ing the debilitating symptoms associated with the pro-
inflammatory state [10,12].
Before the advent of JAK inhibitors as targeted therapy,
available options for the treatment of common clinical
manifestations of MF, such as splenomegaly and debilitat-
ing symptoms, generally had limited, nonlasting efficacy
and/or were poorly tolerated [13,14]. Ruxolitinib, an oral
JAK1/JAK2 inhibitor [15] (formerly INCB018424; Incyte
Corporation, Wilmington, DE, USA), is approved in the
US for the treatment of patients with intermediate or
high-risk MF. Outside the US, ruxolitinib is approved for
the treatment of MF in 42 countries worldwide. Two phase
III studies in patients with MF and platelet counts of attral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Study with Oral JAK Inhibitor Treatment [COMFORT]-I
conducted in the US, Canada, and Australia, and
COMFORT-II conducted in Europe) demonstrated that
ruxolitinib significantly decreased spleen size, reduced
MF-related symptom burden, and improved quality of
life measures compared with placebo (COMFORT-I) and
what at the time was considered best available therapy
(BAT; COMFORT-II) [16,17]. Clinically meaningful im-
provements in spleen size and symptoms were also ob-
served in an ongoing phase II study in patients with MF
and baseline platelet counts of 50 × 109/L to <100 × 109/L
[18]. Long-term data emerging from the COMFORT trials
further suggest that MF patients treated with ruxolitinib
have a survival advantage over those who were randomized
to placebo or BAT [19,20].
Because thrombopoietin and erythropoietin signal
through JAK2 [8], inhibition of JAK2 with ruxolitinib treat-
ment is associated with dose-dependent thrombocytopenia
and anemia [16,17]. In the COMFORT studies, cytopenias
were managed effectively by dose adjustments and treat-
ment interruptions or, in some instances of anemia, with
red blood cell (RBC) transfusions [16,17]. As a result, only
1 patient in the ruxolitinib group discontinued therapy for
anemia and 1 discontinued for thrombocytopenia at the
time of the primary analysis in COMFORT-I [16]. In
COMFORT-II, no patient discontinued ruxolitinib therapy
for anemia and 1 discontinued for thrombocytopenia [17].
This review summarizes lessons learned from the
COMFORT-I trial and from our own clinical experience,
indicating that dose-related cytopenias may occur, as
expected, during the course of therapy and that persist-
ent individualized patient management, especially early
during treatment, can ensure maximum treatment bene-
fit when this medicine is used in appropriate patients
with MF.
Design and participants of the COMFORT-I study
COMFORT-I [16] is a randomized, double-blind, placebo-
controlled, phase III trial in patients with intermediate-2 or
high-risk MF (including primary, post-essential thrombo-
cythemia, and post-polycythemia vera MF) with a baseline
platelet count of at least 100 × 109/L. Of the 309 study par-
ticipants, 155 were randomized to receive ruxolitinib and
154 were randomized to receive placebo. The starting dose
of the blinded study treatment was based on each patient’s
platelet count at baseline, ie, 15 mg twice daily (BID) for
patients with a platelet count of 100 to 200 × 109/L
and 20 mg BID for those with a platelet count >200 ×
109/L. The primary endpoint was the percentage of
patients with at least a 35% reduction from baseline in
spleen volume (as assessed by abdominal imaging) at
week 24. A key secondary endpoint was the percentage
of patients with a 50% or greater improvement in TotalSymptom Score (TSS, comprising individual scores for
night sweats, pruritus, bone or muscle pain, abdominal
discomfort, pain under left ribs, and early satiety) assessed
with the modified Myelofibrosis Symptom Assessment
Form (MFSAF), version 2.0.
Management of treatment-related cytopenias in
COMFORT-I
Onset of anemia and thrombocytopenia
Anemia and thrombocytopenia were the most common
adverse events associated with ruxolitinib treatment and
typically occurred early in the course of therapy [16,17,21].
As shown in Figure 1A and 1B, grade 3 or 4 anemia and
thrombocytopenia were greatest in the first 8–12 weeks of
treatment [16]. Similarly, hemoglobin levels and platelet
counts decreased during the same time frame (Figure 2A
and 2B) [22].
Management of cytopenias
Cytopenias in COMFORT-I were managed successfully
by the use of dose adjustments and RBC transfusions (for
anemia). This management strategy included mandatory
dose reductions at moderate levels of thrombocytopenia
to prevent further decreases in platelet counts and to
minimize the need for temporary or permanent treatment
discontinuation. Doses could be increased step-wise once
blood counts had recovered. This strategy is the basis for
the current dosing recommendations for patients with
platelet counts ≥100 × 109/L (Table 1).
Of 155 patients randomized to ruxolitinib, 56% re-
quired dose reductions; however, more than half of those
patients (49/87) had only a single dose reduction [22].
Most dose reductions occurred during the first 8 to 12
weeks, because decreases in platelet counts primarily oc-
curred during this time period. An analysis of the aver-
age daily doses in the ruxolitinib arm of COMFORT-I
from week 21 to week 24 (final titrated doses) showed
that approximately 60% of patients with baseline platelet
counts of 100 to 200 × 109/L and more than 95% of those
with counts >200 × 109/L attained doses of 10 mg BID or
greater; the median doses in these groups were approxi-
mately 10 and 20 mg BID, respectively [22].
Implementation of mandatory dose reductions and
treatment interruptions was associated with stabilization of
mean platelet counts after the first 8 to 12 weeks of treat-
ment (Figure 2A) [22]. Mean hemoglobin levels recovered
to near baseline levels (Figure 2B) after reaching a nadir of
95 g/L at approximately 8 to 12 weeks of treatment, and
RBC transfusion requirements followed a similar trend
[16,22]. This time course of mean hemoglobin values ob-
served in COMFORT-I was confirmed in COMFORT-II.
After decreasing from a baseline value of 109.3 g/L to a
nadir of 94.1 g/L approximately 12 weeks after treat-
ment initiation, mean hemoglobin levels in the ruxolitinib
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Figure 1 Rates of grade ≥3 thrombocytopenia and anemia in COMFORT-I. (From Verstovsek, et al. A double-blind, placebo-controlled trial of
ruxolitinib for myelofibrosis [16]. © 2012 Massachusetts Medical Society. Reprinted with permission from the Massachusetts Medical Society).
Shown are mean percentages of (A) grade ≥3 thrombocytopenia and (B) grade ≥3 anemia per month over time.
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101.8 g/L by week 24 [17]. Monthly rates of grade 3 or
4 anemia and thrombocytopenia in COMFORT-I de-
creased over time to levels similar to those observed in
the placebo group (Figure 1) [16]. In addition, grade 3 or
4 episodes of bleeding with ruxolitinib were uncommon
(2.6% and 1.3%, respectively) and occurred at rates simi-
lar to those with placebo (2.0% and 1.3%, respectively), an
indication that the mandatory dose reductions and treat-
ment interruptions allowed for effective management of
thrombocytopenia [16].Effect of ruxolitinib dose modifications on efficacy
Although these data illustrate that ruxolitinib-associated
cytopenias can be managed effectively with dose modi-
fications, it is also important to understand how such
dose modifications may affect the efficacy of ruxolitinib
therapy. Final titrated doses of ruxolitinib ≥10 mg BID
(calculated as average daily dose during weeks 21–24)
were associated with clinically meaningful reductions in
spleen volume and improvement in MF-related symp-
toms from baseline to week 24 (Figure 3) [22]. The me-
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Figure 2 Changes in platelet count and hemoglobin in COMFORT-I. (Reprinted from Verstovsek S, et al. Management of cytopenias in patients
with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther [published by Dove Press] [22]).
Shown are mean percentage changes from baseline (BL) with standard errors in (A) platelet count and (B) hemoglobin over time. Final titrated dose
was defined as the average daily dose during weeks 21–24. BID, twice a day.
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in the overall ruxolitinib group (33.0%) [16], with slightly
greater reductions at higher titrated doses. Median re-
ductions in both cytokine and abdominal TSS showed
similar symptom improvements at doses of 10 mg BID
or higher [22].
Ruxolitinib use in clinical practice: lessons from COMFORT-I
Treatment-related cytopenias in MF patients receiving
ruxolitinib are dose-dependent and, given the mechanism
of action of ruxolitinib, they are to be expected. However,in patients with similar blood cell counts at baseline, the
risk of new-onset or worsening cytopenias at a given dose
of ruxolitinib may vary widely. This is likely because of the
considerable heterogeneity of clinical characteristics among
patients—even if they belong to the same risk category—
and the consequent differences in the clinical impact of
ruxolitinib. Therefore, dose adjustments, including their
timing, need to be tailored to each patient and be ac-
companied by careful and appropriate monitoring of
both clinical manifestations (symptoms and splenomegaly)
and hematologic parameters. In particular, aggressive dose
Table 1 Ruxolitinib dose modifications recommended for MF patients with starting platelet count of at least 100 × 109/L*
Dose at time of decline in platelet count Maximum dose based on platelet count after prior
treatment interruption or dose reduction25 mg BID 20 mg BID 15 mg BID 10 mg BID 5 mg BID
Current platelet count New dose to be used
≥125 × 109/L No change No change No change No change No change 20 mg BID
100 to <125 × 109/L 20 mg BID 15 mg BID No change No change No change 15 mg BID
75 to <100 × 109/L 10 mg BID 10 mg BID 10 mg BID No change No change 10 mg BID for 2 weeks; if stable, may increase
to 15 mg BID
50 to <75 × 109/L 5 mg BID 5 mg BID 5 mg BID 5 mg BID No change 5 mg BID for 2 weeks; if stable, may increase
to 10 mg BID
<50 × 109/L Hold Hold Hold Hold Hold Continue holding
*Starting ruxolitinib doses of 15 mg BID for patients with platelet counts of 100 to 200 × 109/L and 20 mg BID for those with a platelet count >200 × 109/L.
Recommended dose modifications based on US prescribing information.
For insufficient response, doses may be increased in 5-mg BID increments to a maximum of 25 mg BID, provided that platelet and neutrophil counts are adequate.
BID, twice daily; MF, myelofibrosis.
Data from Jakafi prescribing information (Incyte Corporation, June 2013).
See full prescribing information for a complete description of FDA-approved dosing of ruxolitinib in patients with intermediate or high-risk MF.
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http://www.jhoonline.org/content/6/1/79increases during the first 3 months of therapy should only
be considered if a patient consistently maintains adequate
platelet counts.
The need for careful patient monitoring and dose
optimization in MF patients receiving treatment is not
unique to ruxolitinib. Similar examples in hematology/
oncology include azacitidine and lenalidomide in patients
with myelodysplastic syndrome. Azacitidine may cause
anemia, neutropenia and thrombocytopenia [23], and
complete blood counts (CBCs) before each treatment cycle
(of 28 days) and as needed are mandated per prescribing






























Figure 3 Changes in spleen volume and symptom scores in COMFOR
et al. Management of cytopenias in patients with myelofibrosis treated wit
Onco Targets Ther [published by Dove Press] [22]). Shown are median perc
symptom score (TSS), abdominal TSS, and cytokine TSS by final titrated rux
includes scores for abdominal discomfort, pain under the ribs on the left si
pruritus, and muscle/bone pain. BID, twice daily.response and toxicity. Lenalidomide is commonly associ-
ated with grade 3 or 4 thrombocytopenia or neutropenia
[24], and dose reductions or treatment interruptions
(depending on specific platelet and absolute neutrophil
counts) are recommended [25].
To manage cytopenias with ruxolitinib therapy in clinical
practice, starting doses should be chosen based on platelet
count and subsequently adjusted based on CBCs, which
need to be monitored every 2 to 4 weeks, or as clinically
indicated, during the first 8 to 12 weeks of therapy or until
a stable dose has been reached. Dose titration in patients
with platelet counts of at least 100 × 109/L should followD 15 mg BID 20 mg BID 25 mg BID
Abdominal TSS Cytokine TSS
T-I by final titrated ruxolitinib dose. (Adapted from Verstovsek S,
h ruxolitinib and effect of dose modifications on efficacy outcomes.
entage changes from baseline to week 24 in spleen volume, total
olitinib dose (average dose during weeks 21–24). Abdominal TSS
de, and early satiety. Cytokine TSS includes scores for night sweats,
Table 2 Ruxolitinib dose modifications recommended for MF patients with a starting platelet count of at least 50 × 109/L
but less than 100 × 109/L*
Current platelet count Dosing recommendation
<25 × 109/L Interrupt treatment
25 to <35 × 109/L with <20% decrease during the prior 4 weeks Decrease dose by 5 mg QD or maintain the current dose if it is 5 mg QD
25 to <35 × 109/L with ≥20% decrease during prior 4 weeks Decrease dose by 5 mg BID or use 5 mg QD if the current dose is
5 mg BID or QD
≥40 × 109/L with ≤20% decrease during prior 4 weeks, ANC >1 × 109/L,
and no dose reductions or treatment interruptions for AE or hematologic
toxicity during the prior 4 weeks
Increase dose by increments of 5 mg QD to a maximum of 10 mg
BID if response is insufficient
*Starting ruxolitinib dose of 5 mg BID. Recommended dose modifications based on US prescribing information.
AE, adverse event; ANC, absolute neutrophil count; BID, twice daily; FDA, US Food and Drug Administration; MF, myelofibrosis; QD, once daily.
Data from Jakafi prescribing information (Incyte Corporation, June 2013).
See full prescribing information for a complete description of FDA-approved dosing of ruxolitinib in patients with intermediate or high-risk MF.
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prescribing information. In addition, dose adjustments and
RBC transfusions may be considered for the management
of anemia.
Similar to the practice in COMFORT-I, starting doses
in COMFORT-II were based on platelet count, and dose
modifications were mandated in cases of developing
thrombocytopenia or neutropenia [17]. Dosing recom-
mendations outside the US essentially follow the practice
in COMFORT-II: starting doses of 15 and 20 mg BID
are recommended for patients with platelet counts of
100 to 200 × 109/L and those with >200 × 109/L, respect-
ively, with close monitoring of blood counts and modifi-
cations in dosing based on platelet or neutrophil counts
as well as clinical response.
Because COMFORT-I and COMFORT-II did not in-
clude patients with baseline platelet counts lower than
100 × 109/L [16], an optimized ruxolitinib dosing strat-
egy for patients with intermediate or high-risk MF and
baseline platelet counts of 50 to 100 × 109/L is being
evaluated in an open-label, phase II study [18]. Preliminary
results supported an update of the US prescribing informa-
tion in June 2013 to include specific recommendations for
the management of patients with a platelet count of at least
50 × 109/L but less than 100 × 109/L at the start of therapy.
Key features of these recommendations are a starting dose
of 5 mg BID and subsequent dose modifications based on
efficacy and changes in platelet count, with a maximum
dose of 10 mg BID (Table 2).
An important lesson from COMFORT-I is that dose
adjustments for cytopenias generally do not affect effi-
cacy. The vast majority of patients in COMFORT-I
attained doses of 10 mg BID or higher after titration,
and these titrated dose levels have been associated with
clinically meaningful reductions in spleen volume and
symptom burden [22]. Thus, patients in clinical practice,
even those with low platelet counts at the beginning of
therapy, may achieve stable doses that are clinically ef-
fective. This conclusion is supported by COMFORT-I dataand consistent with the preliminary results of the ongoing
phase II study of ruxolitinib in patients with baseline plate-
let counts of 50 to 100 × 109/L [18]. In that study, dose ti-
tration of ruxolitinib from a starting dose of 5 mg BID to
final titrated doses of 10 mg BID or higher was associated
with stable mean hemoglobin levels over time as well
as clinically meaningful symptom relief and spleen vol-
ume reduction [18]. These findings further underscore
the importance of initial dose optimization for ensur-
ing continuity of treatment benefit by minimizing dose-
dependent hematologic toxicity while preserving efficacy.
Thus, onset or worsening of cytopenias should not lead to
immediate treatment discontinuation, but rather to careful
management of these events.Conclusions
Ruxolitinib is associated with dose-dependent risks of
thrombocytopenia and anemia in MF patients, as expected
from its mechanism of action; these treatment-related
cytopenias do not indicate a worsening of the underlying
disease. Dose adjustments can be effective in the manage-
ment of these cytopenias without compromising efficacy.
Persistent monitoring and management, particularly over
the first 8 to 12 weeks of ruxolitinib therapy, are necessary
to ensure that patients attain stable doses that are both
safe and provide maximum long-term benefit.
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